Inside Health Policy covers our comment

Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered in detail by Inside Health Policy in “Compounding Pharmacies Say FDA Mismanages Compounding Ad Comm.”

Related posts

Reuters, like many other media outlets, covered Novo Nordisk’s request that the FDA add semaglutide...

The Reuters story, “Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on...

News outlets are moving from writing about the fact that GLP-1 compounding is effectively ending,...